Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture

  • S. Michael Deatley
  • , Michael Y. Aksenov
  • , Marina V. Aksenova
  • , Brad Jordan
  • , John M. Carney
  • , D. Allan Butterfield

Producción científica: Article › revisión exhaustiva

52 Citas (Scopus)

Resumen

Adriamycin (ADM) is an anthracycline anti-neoplastic agent, whose clinical effectiveness is limited by severe side effects, including cardiotoxicity. The toxic effects of ADM are likely to be the consequence of the generation of free radicals. This study demonstrates that ADM induces significant changes in the activity of the oxidative sensitive enzyme creatine kinase (CK) in the heart in vivo and in a cardiomyocyte culture model. The changes observed are likely to reflect the ability of ADM to damage the plasma membrane of cardiac cells and to induce the direct inactivation of CK. The role for ADM-derived free radicals is one of the possible mechanisms for the CK inactivation observed during the ADM treatment. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Idioma originalEnglish
Páginas (desde-hasta)51-62
Número de páginas12
PublicaciónToxicology
Volumen134
N.º1
DOI
EstadoPublished - may 3 1999

Nota bibliográfica

Funding Information:
This work was supported in part by NIH grants (AG-10836; AG-05119) and by a grant from Centaur Pharmaceuticals.

Financiación

This work was supported in part by NIH grants (AG-10836; AG-05119) and by a grant from Centaur Pharmaceuticals.

FinanciadoresNúmero del financiador
Centaur Pharmaceuticals Inc.
National Institutes of Health (NIH)AG-05119
National Institute on AgingP01AG010836

    ASJC Scopus subject areas

    • Toxicology

    Huella

    Profundice en los temas de investigación de 'Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture'. En conjunto forman una huella única.

    Citar esto